About the Journal
Acta Bio Medica (ActaBiomed) is an international peer-reviewed, open access bi-monthly Journal devoted to disseminating new knowledge relating to Experimental and General Medicine field. It publishes only papers in English including Review Articles, Original Articles, Commentaries, Up-to-date Articles, Viewpoints, Case Reports, Humanities topics and Letters to the Editor.
ActaBiomed also publishes 4 annual update sections dedicated to Aging, Paediatric Endocrinology, Adolescent Medicine, Emergency Medicine, Hygiene and Public Health, as well as 2 quarterly supplements committed to Health professions and Orthopedics. Papers are considered for publication only based on the rigor of scientific approach.
Act Biomed is indexed by PubMed, Excerpta Medica, Index Medicus, Embase, Scopus and all articles are directly available from the PubMed. The Journal has a web site (www.actabiomedica.it) and is published by "Mattioli 1885", an experienced Company in scientific journal publication in Italy. ActaBiomed offers three additional services: “ABM-Online-first”, “Fast publication” and "PubMed Now".
The Journal publishes 6 regular issues for year: N. 1 (February issue), N. 2 (April issue), N. 3 (June issue), N. 4 (August issue), N. 5 (October issue), N. 6 (December issue)
ActaBiomed, founded 1806, is expression of the Society of Medicine and Natural Sciences of Parma, Parma, Italy, instituted in 1735, as well as one of the oldest continuously published Journals in the world.
The policies of the journal are based on the guidelines set forth by the International Committee of Medical Journal Editors. The journal follows the code on good publication practice, “Core Practice,” set forth by the Committee on Publication Ethics (http://publicationethics.org/).
Acta Biomedica (ActaBiomed) is published by Mattioli1885. Mattioli 1885 grants editorial freedom to the Editor of the journal.
Open Access Policy
All research articles published in ActaBiomed are freely and permanently accessible online. The authors retain the copyright for their published work.
It is the responsibility of the Authors of an article published in ActaBiomed to have contributed in a meaningful and identifiable way to the design, performance, analysis, and reporting of the manuscript.
Authors must obtain ethics committee approval and informed patient consent for any experimental use of a novel procedure or tool where a clear clinical advantage based on clinical need was not apparent before treatment.
The corresponding author, also on behalf of all the other Authors, must declare the existence or otherwise of financial connections (consultancies, ownership of shares, patents, etc.) that might constitute a potential conflict of interest in relation to the subject matter of the article. In the case of existence of any such financial connections, the authors concerned must declare them in a brief but complete definition at the end of the article, before the references. If no conflict of interest exists the corresponding Author should type: "Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article".
Without these declarations the submission process will cannot progress.
ActaBiomed permits only one corresponding author per manuscript submission. This Author is solely responsible for all correspondence with the ActaBiomed and will receive all emails regarding forms, authorship issues, manuscript files, etc.
For more information: Guidelines for Authors
Starting from 1st January 2021, a APC of 300,00 € (plus VAT) will be due for the accepted papers that will indexed in PubMed. The fee for the articles submitted starting from 1-1-2021 should be paid after the acceptation of the article and before the publication. The corresponding authors are responsible for making the payment or arranging it through their institutions. After that payment we will proceed with the publication. For Authors asking "fast publication", a further charge of 200,00 € will be added to cover the costs for this fast-additional service. The article will be published in the first next available publishing issue. Letters to the Editor as well as reviews, editorial papers, and all articles requested by the Editor in Chief and Section Editors will be published free of charge. Visit Article Processing Charge (APC) for more information
At this time, no advertising for the Journal is permitted.
Peer Review Process
The Journal follows a double-blind review process to evaluate manuscripts for scientific accuracy, novelty, and importance. Visit ActaBiomed Guidelines for more information.
The Journal has adopted a continuous publication model. The articles are published online as the final and complete version. All articles will be assigned to one of 6 bimonthly issues each year, with the exception of a Supplement at the Editor’s discretion: Issue no. 1: February 31; Issue no. 2: April 30; Issue no. 3: Jun 31; Issue no. 4: August 30; Issue no 5: October 31 Issue no 6: December 31
Statements and opinions expressed in the articles published in ActaBiomed are those of the author(s) and not necessarily those of the editorial board or the publisher. Although the editors and reviewers make every effort to ensure the validity of published manuscripts, the final responsibility rests with the authors, not with the Journal, its editors, or the publisher.
The corresponding Authors must disclaim that the submitted paper has not already been published or submitted for publication elsewhere. Manuscript must be original and not contains parts taken from other publications.
The company Mattioli 1885 S.r.l. guarantees that the personal data collected will be processed in a lawful, correct, transparent manner and only for the purposes for which they were collected and, in any case, in compliance with EU Reg. N. 679/2016 and of the Legislative Decree n. 101/2018, as well as any other provision on the subject
Policies on Conflict of Interest, Human and Animal rights, and Informed Consent
Acta Bio Medica requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests’ section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read “The authors have declared that no competing interests exist.” Editors may ask for further information relating to competing interests. Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists.
Competing interests may be financial or non-financial. A competing interest exists when the authors’ interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.
Financial competing interests include (but are not limited to):
– Receiving reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of the article, either now or in the future.
– Holding stocks or shares in an organization that may in any way gain or lose financially from the publication of the article, either now or in the future.
– Holding, or currently applying for, patents relating to the content of the manuscript.
– Receiving reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript.
– Non-financial competing interests
– Non-financial competing interests include (but are not limited to) political, personal, religious, ideological, academic, and intellectual competing interests. If, after reading these guidelines, you are unsure whether you have a competing interest, please contact the Editor.
Authors from pharmaceutical companies, or other commercial organizations that sponsor clinical trials, should declare these as competing interests on submission. They should also adhere to the Good Publication Practice guidelines for pharmaceutical companies, which are designed to ensure that publications are produced in a responsible and ethical manner. The guidelines also apply to any companies or individuals that work on industry-sponsored publications, such as freelance writers, contract research organizations and communications companies.
Human and animal rights
All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s)’ institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.
Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. If a study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee that granted the exemption). Further information and documentation to support this should be made available to Editors on request. Manuscripts may be rejected if the Editor considers that the research has not been carried out within an appropriate ethical framework. In rare cases, Editors may contact the ethics committee for further information.
If a study has not been submitted to an ethics committee prior to commencing, retrospective ethics approval usually cannot be obtained and it may not be possible to consider the manuscript for peer review. How to proceed in such cases is at the Editor(s)’ discretion.
Authors reporting the use of a new procedure or tool in a clinical setting, for example as a technical advance or case report, must give a clear justification in the manuscript for why the new procedure or tool was deemed more appropriate than usual clinical practice to meet the patient’s clinical need. Such justification is not required if the new procedure is already approved for clinical use at the authors’ institution. Authors will be expected to have obtained ethics committee approval and informed patient consent for any experimental use of a novel procedure or tool where a clear clinical advantage based on clinical need was not apparent before treatment.
For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript.
For all manuscripts that include details, images, or videos relating to individual participants, written informed consent for the publication of these must be obtained from the participants (or their parent or legal guardian in the case of children under 16) and a statement to this effect should appear in the manuscript. If the participant has died, then consent for publication must be sought from the next of kin of the participant. This documentation must be made available to Editors on request, and will be treated confidentially. In cases where images are entirely unidentifiable and there are no details on individuals reported within the manuscript, consent for publication of images may not be required. The final decision on whether consent to publish is required lies with the Editor.
Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.
A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. If a study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee that granted the exemption and the reasons for the exemption). The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.
For experimental studies involving client-owned animals, authors must also document informed consent from the client or owner and adherence to a high standard (best practice) of veterinary care.
Field studies and other non-experimental research on animals must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. A statement detailing compliance with relevant guidelines and/or appropriate permissions or licences must be included in the manuscript. We recommend that authors comply with the Convention on the Trade in Endangered Species of Wild Fauna and Flora and the IUCN Policy Statement on Research Involving Species at Risk of Extinction.
Authors are strongly encouraged to conform to the Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines, developed by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), for reporting animal studies.
For studies reporting livestock trials with production, health and food-safety outcomes, authors are encouraged to adhere to the Reporting Guidelines for Randomized Controlled Trials in Livestock and Food Safety (REFLECT).
ICMJE best practice standards
Mattioli 1885 requires the Authors and Editors of its journals to follow the recommendations by the International Committee of Medical Journal Editors (ICMJE), which reviews best practice and ethical standards in the conduct and reporting of research and other material published in medical journals. It is Mattioli 1885’ conviction that following these recommendations supports the accurate, clear, reproducible, and unbiased creation and distribution of scientific journal articles. Please download or review these recommendations here.
Corrections and retractions
Rarely, it may be necessary for Mattioli 1885 to publish [corrections] to, or [retractions] of, articles published in its journals, so as to maintain the integrity of the academic record.
In line with BioMed Central's [Permanency] policy, [corrections] to, or [retractions] of, published articles will be made by publishing an Erratum or a Retraction article, without altering the original article in any way other than to add a prominent link to the Erratum/Retraction article. The original article remains in the public domain and the subsequent Erratum or Retraction will be widely indexed. In the exceptional event that material is considered to infringe certain rights or is defamatory, we may have to remove that material from our site and archive sites.
It may be possible for minor corrections to published articles to be made by the original author(s) posting a comment on the published article. This would only be appropriate where the changes do not affect the results or conclusions of the article. See our [Comments] policy for further information on posting comments.
Changes to published articles that affect the interpretation and conclusion of the article, but do not fully invalidate the article, will, at the Editor(s)’ discretion, be corrected via publication of an Erratum that is indexed and linked to the original article. Changes in authorship of published articles are corrected via an Erratum..
On rare occasions, when the scientific information in an article is substantially undermined, it may be necessary for published articles to be retracted. Mattioli 1885 will follow the COPE guidelines in such cases. Retraction articles are indexed and linked to the original article.